Protective effect of CCR2-64I and not of CCR5-Δ32 and SDF1-3'A in pediatric HIV-1 infection
The effects of chemokine and chemokine receptor genetic polymorphisms such as stromal derived factor 1 (SDF1-3'A), CCR2-64I, and CCR5-Δ32 associated with HIV-1 transmission and/or rate of disease progression in infected study subjects remain highly controversial and have been analyzed primarily...
| Autores: | , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2000 |
| País: | Argentina |
| Institución: | Consejo Nacional de Investigaciones Científicas y Técnicas |
| Repositorio: | CONICET Digital (CONICET) |
| Idioma: | inglés |
| OAI Identifier: | oai:ri.conicet.gov.ar:11336/149060 |
| Acceso en línea: | http://hdl.handle.net/11336/149060 |
| Access Level: | acceso abierto |
| Palabra clave: | CCR2 CCR5 CHEMOKINE RECEPTORS HIV-1 PEDIATRIC AIDS SDF1 VERTICAL TRANSMISSION https://purl.org/becyt/ford/3.1 https://purl.org/becyt/ford/3 |
| Sumario: | The effects of chemokine and chemokine receptor genetic polymorphisms such as stromal derived factor 1 (SDF1-3'A), CCR2-64I, and CCR5-Δ32 associated with HIV-1 transmission and/or rate of disease progression in infected study subjects remain highly controversial and have been analyzed primarily only in adults. We have investigated whether these polymorphisms may provide similar beneficial effects in children exposed to HIV-1 perinatally. The prevalence of CCR2-64I allele was significantly increased (p = .03) and the CCR2-64I genotype distribution was not in Hardy-Weinberg equilibrium, among HIV-1-exposed uninfected infants. Moreover, in the HIV-1- infected group, a delay to AIDS progression was observed among carriers of CCR2-64I allele. This is the first report that suggests a protective role of CCR2-64I allele in mother-to-infant HIV-1 transmission and documents a delay in disease progression, after the child has been infected with HIV-1. However, SDF1-3'A and CCR5-Δ32 alleles did not modify the rate of HIV-1 transmission or disease progression in HIV-1-infected children. |
|---|